Company’s 36-month beta value is 0.92.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATHE is 8.45M, and currently, short sellers hold a 1.76% ratio of that floaft. The average trading volume of ATHE on December 27, 2024 was 47.20K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATHE) stock’s latest price update
Alterity Therapeutics Ltd ADR (NASDAQ: ATHE)’s stock price has gone rise by 28.53 in comparison to its previous close of 2.45, however, the company has experienced a 45.79% increase in its stock price over the last five trading days. globenewswire.com reported 2024-12-04 that – ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-201 Phase 2 trial, a randomized, double-blind, placebo-controlled investigation in early-stage multiple system atrophy (MSA), has completed the study. With the achievement of this milestone, topline results are expected to be reported in late January or early February 2025.
ATHE’s Market Performance
ATHE’s stock has risen by 45.79% in the past week, with a monthly rise of 199.88% and a quarterly rise of 153.95%. The volatility ratio for the week is 12.70% while the volatility levels for the last 30 days are 12.69% for Alterity Therapeutics Ltd ADR The simple moving average for the past 20 days is 48.82% for ATHE’s stock, with a 88.18% simple moving average for the past 200 days.
Analysts’ Opinion of ATHE
Many brokerage firms have already submitted their reports for ATHE stocks, with Maxim Group repeating the rating for ATHE by listing it as a “Buy.” The predicted price for ATHE in the upcoming period, according to Maxim Group is $8 based on the research report published on December 12, 2024 of the current year 2024.
ATHE Trading at 104.60% from the 50-Day Moving Average
After a stumble in the market that brought ATHE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.29% of loss for the given period.
Volatility was left at 12.69%, however, over the last 30 days, the volatility rate increased by 12.70%, as shares surge +197.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +149.98% upper at present.
During the last 5 trading sessions, ATHE rose by +45.79%, which changed the moving average for the period of 200-days by +84.69% in comparison to the 20-day moving average, which settled at $2.12. In addition, Alterity Therapeutics Ltd ADR saw 26.47% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ATHE
Current profitability levels for the company are sitting at:
- -5.66 for the present operating margin
- 0.96 for the gross margin
The net margin for Alterity Therapeutics Ltd ADR stands at -4.49. The total capital return value is set at -2.27. Equity return is now at value -102.86, with -80.90 for asset returns.
Currently, EBITDA for the company is -19.57 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of 4.46. The receivables turnover for the company is 1.37for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.54.
Conclusion
In a nutshell, Alterity Therapeutics Ltd ADR (ATHE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
